Evidence map›Paper›PMID 39356296›Full record

SynthesisCalcified tissue international2024

Short-Term Changes in Bone Metabolism Among Transgender Men Starting Gender-Affirming Hormone Therapy: A Systematic Review and Meta-analysis.

Daniele Tienforti, Lorenzo Marinelli, Jeroen Vervalcke, Luca Spagnolo, Federica Antolini, Andreina Bichiri, Marco Giorgio Baroni, Giovanna Motta, Guy T'Sjoen, Arcangelo Barbonetti

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Calcified tissue international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniele Tienforti *Andrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy. danieletienforti@gmail.com.ORCID 0000-0002-9359-7955
Lorenzo Marinelli *Division of Endocrinology, Diabetes, and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Jeroen VervalckeDepartment of Endocrinology, Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.
Luca SpagnoloAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy.
Federica AntoliniAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy.
Andreina BichiriDivision of Endocrinology, Diabetes, and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Marco Giorgio BaroniAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy.
Giovanna MottaDivision of Endocrinology, Diabetes, and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Guy T'SjoenDepartment of Endocrinology, Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.
Arcangelo BarbonettiAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transgender and gender diverse individuals experience a gender identity that differs from the sex assigned at birth. Some transgender men may request testosterone to induce virilization; however, its impact on bone health remains to be fully elucidated. The objective of this systematic review and meta-analysis was to evaluate the modifications in bone metabolism over a short-term period among transgender men initiating testosterone therapy. A systematic search was conducted in PubMed, Scopus, Web of Science, and Cochrane Library. The articles of interest had to report longitudinal evaluation conducted among transgender men, before starting testosterone and after 12 and 24 months of therapy. The analyzed parameters were BMD, calcium, phosphate, 25OHD, PTH, P1NP, BAP, osteocalcin and CTx. Mean differences with 95% coefficient intervals were combined using random effects models. Funnel plot, Egger's test, and trim-and-fill analysis were used to assess publication bias. Fourteen studies met the inclusion criteria, including 1484 subjects. In absence of heterogeneity, BMD did not significantly change at lumbar spine, hip, femoral neck, and whole-body evaluations. Calcium, phosphate, 25OHD and PTH remained stable over time. Regarding bone turnover markers, only P1NP showed a statistically significant increase after 12 months of T therapy, in absence of heterogeneity (SMD 0.61 mcg/l; 95% CI: 0.40-0.83; p < 0.0001; I

Indexed as

Bone and BonesBone DensityTestosteroneTransgender PersonsBone RemodelingFemaleHumansMaleTestosteroneBMDBone turnover markersGAHTGender incongruenceTestosteroneTransmen

Identifiers

PMID39356296
PMCPMC11531450

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.